Genetic adjuvants for immunotherapy

• US 8,603,458 B2
• Filed: 06/02/2009
• Issued: 12/10/2013
• Est. Priority Date: 09/05/2002
• Status: Expired due to Fees

• Current Assignee: University of South Florida (State University System of Florida)
• Original Assignee: University of South Florida (State University System of Florida)
• Inventors: Mohapatra, Shyam S., Kumar, Mukesh
• Primary Examiner(s): Noble, Marcia S
• Application Number:
  US12/476,896
• Publication Number:
  US 20090280143A1
• Time in Patent Office: 1,652 Days
• Field of Search: 424/93.2, 424/193.1, 514/44.R
• US Class Current: 424/93.2
• CPC Class Codes: A61K 2039/53 DNA (RNA) vaccination
• CPC Class Codes: A61K 2039/55522 Cytokines; Lymphokines; Interferons
• CPC Class Codes: A61K 2039/55538 IL-12
• CPC Class Codes: A61K 38/208 IL-12
• CPC Class Codes: A61K 38/217 IFN-gamma
• CPC Class Codes: A61K 39/35 Allergens
• CPC Class Codes: A61K 39/36 from pollen
• CPC Class Codes: A61K 39/39 characterised by the immunostimulating additives, e.g. chemical adjuvants
• CPC Class Codes: A61P 37/04 Immunostimulants

Abstract

The present invention pertains to methods and pharmaceutical compositions for modulating an immune response. The method of the present invention involves administration of an effective amount of nucleic acid molecules encoding interleukin-12 (IL-12), interferon-gamma (IFN-γ), or a combination thereof, to a patient in need of such treatment. The pharmaceutical compositions of the invention contain nucleic acid molecules encoding IL-12 and/or IFN-γ and an operably-linked promoter sequence. In another aspect, the present invention concerns expression vectors containing a nucleotide sequence encoding IL-12 and IFN-γ, and an operably-linked promoter sequence. In another aspect, the present invention concerns cells genetically modified with a nucleotide sequence encoding IL-12 and IFN-γ.

Claims

1. A method for modulating an immune response, comprising administering host cells and an antigen to a mammal, wherein the host cells have been obtained from the mammal and have been genetically modified with an expression vector to produce, or increase production of, p35 and p40 subunits of IL-12, and IFN-γ

, by the host cells, wherein the expression vector comprises a nucleic acid encoding the p35 and p40 subunits of IL-12 and IFN-γ

operably linked to a promoter, wherein the p35 and p40 subunits of IL-12 and IFN-γ

are secreted by the administered host cells in the mammal, and wherein said administering of the host cells and the antigen result in an increase of IFN-γ and

IL-2 production, an increase of IgG2a specific to the antigen, a decrease of IL-4 production, and reduced serum IgE in the mammal.

2. The method of claim 1, wherein the mammal is a human, wherein the IL-12 is human IL-12, and wherein the IFN-γ

is human IFN-γ

.

3. The method of claim 2, wherein the p35 subunit comprises the amino acid sequence of SEQ ID NO:

8, and wherein the p40 subunit comprises the amino acid sequence of SEQ ID NO;

10.

4. The method of claim 2, wherein the IFN-γ

comprises the amino acid sequence of SEQ ID NO;

12.

5. The method of claim 1, wherein the antigen is selected from the group consisting of a protein, peptide, glycoprotein, carbohydrate, lipid, glycolipid, hapten conjugate, recombinant nucleotides, killed or attenuated organism, toxin, toxoid, and organic molecule.

6. The method of claim 1, wherein the host cells do not express endogenous p35 and p40 subunits of IL-12 and IFN-γ

.

7. The method of claim 1, wherein the expression vector comprises a DNA plasmid or viral vector.